Taiyen Biotech Co (TPE:1737) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

What is Taiyen Biotech Co LT-Debt-to-Total-Asset?

Taiyen Biotech Co TPE:1737 83 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates TPE:1737 with a GF Score™ of 83/100 and a GF Value™ of NT$32.08 (Fairly Valued). The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Taiyen Biotech Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Taiyen Biotech Co's long-term debt to total assets ratio declined from Dec. 2024 (0.00) to Dec. 2025 (0.00). It may suggest that Taiyen Biotech Co is progressively becoming less dependent on debt to grow their business.

Taiyen Biotech Co (TPE:1737) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Taiyen Biotech Co LT-Debt-to-Total-Asset Related Terms

Taiyen Biotech Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Taiyen Biotech Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiyen Biotech Co LT-Debt-to-Total-Asset Chart

Taiyen Biotech Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.00

Taiyen Biotech Co Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

83GF Score

Taiyen Biotech Co Ltd TPE:1737

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Taiyen Biotech Co LT-Debt-to-Total-Asset Calculation

Taiyen Biotech Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	26.563	/	8262.561
	=	0.00

Taiyen Biotech Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	26.563	/	8262.561
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Taiyen Biotech Co (TPE:1737) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Taiyen Biotech Co and its competitors.

Is Taiyen Biotech Co's LT-Debt-to-Total-Asset too high?

Taiyen Biotech Co's current LT-Debt-to-Total-Asset is 0.00. Overall, Taiyen Biotech Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Taiyen Biotech Co's LT-Debt-to-Total-Asset compare to PG and CL?

Taiyen Biotech Co's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Consumer Packaged Goods company?

A good LT-Debt-to-Total-Asset depends on the Consumer Packaged Goods industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Taiyen Biotech Co and its competitors. Taiyen Biotech Co's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Taiyen Biotech Co stock overvalued right now?

Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.08, compared to a current price of NT$31.90 — trading 0.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Taiyen Biotech Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?

Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued. The current stock price of NT$31.90 is trading 0.6% below its estimated GF Value™ of NT$32.08. GuruFocus considers Taiyen Biotech Co to be Fairly Valued.

Key valuation signals for TPE:1737:

LT-Debt-to-Total-Asset: 0.00
GF Value™: NT$32.08 vs. price of NT$31.90 (0.6% below fair value)
GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiyen Biotech Co Business Description

Industry Consumer Defensive Consumer Packaged Goods

Comparable Companies ROCO:6523 TPE:4137 ROCO:6703 TPE:1730 TPE:1817 TPE:9919 TPE:6504 ROCO:6574 TPE:3557 TPE:6666 PG XPAR:OR LSE:ULVR CL BOM:500696 LSE:RKT KVUE KMB XTER:HEN3 EL

Address No. 297, Section 1, Chien-Kang Road, South District, Tainan, TWN

Website https://www.tybio.com

Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.

83GF Score

Get the complete analysis for TPE:1737

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.90

Price

NT$32.08

GF Value

View TPE:1737 Analysis

See LT-Debt-to-Total-Asset data for all stocks →